Company intelligence / Profile preview

CMS Medical

China

Ownership: Private
Employees: ~4000
Development stage: Other

Overview

CMS focuses on clinical development, registration, and commercialization of innovative products, with Phase III ongoing for MG-K10 (long-acting anti-IL-4Rα monoclonal antibody for moderate-to-severe atopic dermatitis). Multiple innovative drugs have marketing applications accepted in China.

Therapeutic areas: ImmunologyOtherCardiovascularNeurologyDermatologyGastroenterologyOphthalmology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

TrinomabAstraZenecaCambridge Judge Business School

Beyond the preview

Go deeper on CMS Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMS Medical.

Explore the full profile